ArticleBritish journal of cancer2011
Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab.
Article in British journal of cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 85 citations in OpenAlex.
- Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma.Journal of hematology & oncology · 2018Trial
- Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.International journal of cancer · 2017Trial
- Trial
- A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma.Journal of hepatology · 2014Trial
- A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2012Trial
- Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2011Trial
- Proteomic analysis of combined IGF1 receptor targeted therapy and chemotherapy identifies signatures associated with survival in breast cancer patients.Oncotarget · 2020Article
- Advances in insulin-like growth factor biology and -directed cancer therapeutics.Advances in cancer research · 2020Review
- Therapeutic Targeting of the IGF Axis.Cells · 2019Review
- Receptor Tyrosine Kinase-Targeted Cancer Therapy.International journal of molecular sciences · 2018Review
- The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link.Frontiers in endocrinology · 2015Review
- Context Sensitive Modeling of Cancer Drug Sensitivity.PloS one · 2015Article
- Insulin-like growth factor and epidermal growth factor signaling in breast cancer cell growth: focus on endocrine resistant disease.Analytical cellular pathology (Amsterdam) · 2015Review
- Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells.Oncology letters · 2014Article
- Can we unlock the potential of IGF-1R inhibition in cancer therapy?Cancer treatment reviews · 2014Review
- Retraction: molecular analysis of non-small cell lung cancer identifies subsets with different sensitivity to insulin-like growth factor i receptor inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research · 2014Article
- Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer.Clinical lung cancer · 2014Article
- The IGF Hormonal Network in Endometrial Cancer: Functions, Regulation, and Targeting Approaches.Frontiers in endocrinology · 2014Review
- Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy.Journal of Cancer · 2013Review
- Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling.Cancer prevention research (Philadelphia, Pa.) · 2013Article
Corrections and comments
- Retraction · 2012-12-04Unreliable Results and/or Conclusions ·
- Commented on by
- Commented on by
- Retracted
Authors and funding
11 authors at 8 institutions in 4 countries.
Funding
Abstract
backgroundPhase III trials of the anti-insulin-like growth factor type 1 receptor (IGF-IR) antibody figitumumab (F) in unselected non-small-cell lung cancer (NSCLC) patients were recently discontinued owing to futility. Here, we investigated a role of free IGF-1 (fIGF-1) as a potential predictive biomarker of clinical benefit from F treatment. MATERIALS AND
methodPre-treatment circulating levels of fIGF-1 were tested in 110 advanced NSCLC patients enrolled in a phase II study of paclitaxel and carboplatin given alone (PC) or in combination with F at doses of 10 or 20 mg kg(-1) (PCF10, PCF20).
resultsCox proportional hazards model interactions were between 2.5 and 3.5 for fIGF-1 criteria in the 0.5-0.9 ng ml(-1) range. Patients above each criterion had a substantial improvement in progression-free survival on PCF20 related to PC alone. Free IGF-1 correlated inversely with IGF binding protein 1 (IGFBP-1, ρ=-0.295, P=0.005), and the pre-treatment ratio of insulin to IGFBP-1 was also predictive of F clinical benefit. In addition, fIGF-1 levels correlated with tumour vimentin expression (ρ=0.594, P=0.021) and inversely with E-cadherin (ρ=-0.389, P=0.152), suggesting a role for fIGF-1 in tumour de-differentiation.
conclusionFree IGF-1 may contribute to the identification of a subset of NSCLC patients who benefit from F therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.